Molecular Crosstalk between Chromatin Remodeling and Tumor Microenvironment in Multiple Myeloma.
Chandraditya ChakrabortySrimoyee MukherjeePublished in: Current oncology (Toronto, Ont.) (2022)
Multiple myeloma (MM) is a complex disease driven by numerous genetic and epigenetic alterations that are acquired over time. Despite recent progress in the understanding of MM pathobiology and the availability of innovative drugs, which have pronounced clinical outcome, this malignancy eventually progresses to a drug-resistant lethal stage and, thus, novel therapeutic drugs/models always play an important role in effective management of MM. Modulation of tumor microenvironment is one of the hallmarks of cancer biology, including MM, which affects the myeloma genomic architecture and disease progression subtly through chromatin modifications. The bone marrow niche has a prime role in progression, survival, and drug resistance of multiple myeloma cells. Therefore, it is important to develop means for targeting the ecosystem between multiple myeloma bone marrow microenvironment and chromatin remodeling. Extensive gene expression profile analysis has indeed provided the framework for new risk stratification of MM patients and identifying novel molecular targets and therapeutics. However, key tumor microenvironment factors/immune cells and their interactions with chromatin remodeling complex proteins that drive MM cell growth and progression remain grossly undefined.
Keyphrases
- multiple myeloma
- genome wide
- drug resistant
- bone marrow
- gene expression
- dna damage
- transcription factor
- dna methylation
- copy number
- multidrug resistant
- end stage renal disease
- mesenchymal stem cells
- newly diagnosed
- stem cells
- induced apoptosis
- chronic kidney disease
- ejection fraction
- prognostic factors
- papillary thyroid
- cell proliferation
- endoplasmic reticulum stress
- cell cycle arrest
- single molecule
- cystic fibrosis
- human health